Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaTSCAN SPECT in Differentiating Lewy Body Dementia
NCT00209456Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Nov 2003
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ioflupane I-123 in Lewy body dementia (LBD), sponsored by GE HealthCare. Primary endpoint: Sensitivity and Specificity of DaTSCAN SPECT. Started Nov 2003; status: completed.
02
Drugs
ioflupane I-123
03
Conditions
Lewy body dementia (LBD)
Beyond the preview
Go deeper on NCT00209456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209456.